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Summary We have used polymerase chain reaction (PCR) to measure keratin 19 mRNA in order to detect
breast cancer cells invading axillary lymph nodes. In a consecutive series of 125 patients with primary breast
cancer, 75 patients had no evidence of lymph node involvement by conventional histology. A total of 530
lymph nodes from these patients were examined and 106 (20%) gave a keratin 19 product detectable by
Southern hybridisation. This correlated with primary tumour size (P<0.001). These 106 nodes came from 23
patients. Thus, using this technique, 23/75 (30.6%) patients were found to have evidence of lymph node
involvement who would otherwise have been designated lymph node negative.
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Mortality from breast cancer exceeds 12 000 women annually
in the UK, and almost all women die as a result of distant
metastases. At presentation, over 95% will have no evidence
of metastatic disease on clinical, biochemical and radiological
examination (Coombes et al., 1980). Even after apparently
curative surgery, when all the local disease has been
eradicated and the axillary nodes show no evidence of
histological involvement by tumour, approximately 30% of
women relapse with metastases within 5 years (Fisher et al.,
1981). Many of these women will not have received adjuvant
chemotherapy as, particularly in premenopausal patients, this
is principally given to patients with histological evidence of
node involvement.
While several groups have used immunohistological
methods to demonstrate axillary node micrometastases that
were previously missed on histological examination in a
proportion of cases (Trojani et al., 1987), a review of these
studies showed that only 13% of2400 patients converted from
node negative to node positive (Neville et al., 1990). Recently,
we reported that measurements of keratin 19 (K19) mRNA
following RT-PCR amplification improved detection of
tumour cells in lymph nodes (Schoenfeld et al., 1994). K19 is
universally expressed in breast cancers (Bartek et al., 1985) and
is not present in normal lymph nodes (Traweek et al., 1993).
In this extended study of 125 consecutive patients, we
show that this is a more sensitive way to detect micro-
metastases in lymph nodes.
Materials and methods
Patients
All patients gave written, informed consent to this study.
Lymph nodes were collected from 125 patients undergoing
axillary dissection for breast cancer at Charing Cross
Hospital, London, UK, from January 1993 to June 1994.
Table I shows the clinical and pathological details. Distant
metastases were not detected in any patient by routine
staging using isotopic bone scanning, liver ultrasound and
chest radiography (Table I).
Tumour grade (Bloom et al., 1957), pathological size and
presence of vascular invasion were recorded. Oestrogen and
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progesterone receptor status was assessed by ligand binding
assay or by immunohistochemistry using the lD5 antibody
(Dako) and progesterone receptor immunocytochemical assay
(PR-ICA) (Abbott Laboratories, Chicago, IL, USA) respec-
tively. For K19 immunocytochemistry, we examined four
paraffin sections from each of 46 lymph nodes from 33
patients using antibody RCK 108 (Dako, UK).
Conventional histological examination showed evidence of
lymph node involvement in 50/125 (40%) patients: 41% of
these had four or more nodes involved. In the lymph node-
negative group, the number of nodes examined using RT-
PCR is shown in Table II.
As a control group, 28 lymph nodes were collected from
20 patients admitted for a variety of conditions but none of
whom had any signs of an epithelial malignancy.
The data were analysed by the chi-square test and the two
sample t-test.
RNA extraction, RT-PCR amplification and Southern
hybridisation
The detailed procedures have been described by our group
(Schoenfeld et al., 1994). Lymph nodes were dissected out
taking great care to avoid contamination by using surgical
gloves. Each node was then bisected: one half for histological
examination and one half for mRNA analysis. Total cellular
RNA was extracted using the acid guanidinium-phenol-
chloroform technique, using RNA,ol (Biogenesis, Bourne-
mouth, UK).
DNAase treatment of RNA To remove any contaminating
DNA, a sample of the extracted RNA preparation was
treated with RNAase-free DNAase 1 (Boehringer Man-
nheim). To a total volume of 100 M1 containing 12 Mg of
RNA was added, 10 mM magnesium chloride, 0.1 mM
dithiothreitol, 50 mM Tris-HCl and 10 units of enzyme. The
mixture was then incubated at 37°C for 1 h. The enzyme was
heat inactivated, and the RNA was ethanol precipitated
following phenol-chloroform extraction and was resus-
pended in water.
Reverse transcription First-strand cDNA was synthesised by
using MMLV reverse transcriptase. RNA (4 jug in 12 MI of
water) was added to 1 p1 of enzyme (200 units), 4 jMl of
5 x reaction buffer (250 mM Tris-HCl, pH 8.3, 375 mM
potassium chloride and 15 mm magnesium chloride), 1 jl of
dNTP (20 mm concentrations each of dATP, dCTP, dGTP
and dTTP), 1 Mil of dithiothreitol and 1 jil of randomKeratin 19 mRNA measurement in breast cancer
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Table I Clinical and pathological data of the study group and correlation with the presence of K19 mRNA
No. of aP-value (lymph P-value
patients node-negative patients) (all patients)
Age
Range 24-74 years
Mean 52 years
Premenopausal
Post-menopausal
Surgery
Wide local excision
(biateral carcinoma in one patient)
Mastectomy
Tumour size (cm)
(invasive tumours)
0-1.0
1.1-2.0
2.1 -5.0
>5
Not measured
Tumour type
Infiltrating ductal carcinoma (IDC)
Infiltrating lobular carcinoma (ILC)
Ductal carcinoma in situ with microinvasion
Medullary
Mucinous
Alveolar
Grade
1
2
3
Not stated
Vascular invasion
Present
Absent
Not known
Oestrogen receptor
Positive
Negative
Progesterone receptor
Positive
Negative
Not known
49
76
102
23
25
60
29
2
9
107
9
5
2
1
10
61
36
19
45
55
25
82
43
75
50
65
NS
NS
<0.05
NS
0.05
NS
NS
NS
NS
NS
<0.001
NS
0.01
0.01
NS
NS
aThis column shows the 'P-value' ofthe relationship when only nodes that were removed from the 75 lymph
node-negative patients are included. NS, not significant.
Table II The number of histologically node-negative patients with
K19-positive nodes by RT-PCR vs the number of nodes examined
by RT-PCR
No. ofnodes
examined by No. ofK19-positive nodes by RT-PCR
RT-PCR 0 1 2 3 4 5 6 7 8
1 1 1
2 3 3
3 7
4 12 3 1
5 11 2 2 1
6 12 2 1 3 1
7 5 1
8 1 1 1
hexamers (250 ng) to form a total reaction volume of 20 jMl.
Following incubation at 42°C for 1 h, the mixture was heated
to 95°C, snap cooled and stored at -20°C. In each
experiment, an additional tube which contained all the
reagents except the enzyme was included as a blank control.
Polymerase chain reaction Specific cDNA sequences were
amplified in a reaction mix (100 jl) composed of 1-4 jMl of
cDNA (equivalent to 100-400 ng of RNA), 2 units of Taq
polymerase, 2 mM magnesium chloride, 200 jM dNTP,
200 ng of each of the 5' and 3' sequence-specific primers,
and buffer containing, in final concentrations, 67 mM Tris-
HCl, pH 8.8 (at 25°C), 16.6 mM ammonium sulphate, 0.45%
Triton X-100 and 200 jg ml-' gelatin, and overlaid with
50 pl of mineral oil.
Forty cycles of amplification were performed with
denaturation at 94°C for 1 min, annealing at 55°C for
1 min and extension at 72°C for 1 min with an extra 10 min
extension for the last cycle.
Restriction enzyme analysis To verify the identity of the
PCR products obtained with the K19 primers, a sample
(50 pl) was purified by using the Magic DNA clean-up
system (Promega), digested with 36 units of HaeII
(Boehringer Mannheim) in buffer containing Tris-acetate
(33 mM), potassium acetate (66 mM), magnesium acetate
(10 mM) and dithiothreitol (0.5 mM, pH 7.9) and incubated
at 37°C for 16-20 h. An aliquot was electrophoresed on
1.5% agarose alongside undigested DNA, and bands were
visualised with ethidium bromide.
Gel electrophoresis, Southern blotting and hybridisation Ali-
quots of chloroform-extracted PCR products (10 ll) were
electrophoresed at 100 V for 1-2 h on a 1.5% agarose gel
containing ethidium bromide in Tris-acetate EDTA buffer,
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together with size marker HaeIII-digested FX174 or the
Cambio DNA ladder and transferred onto HyBond N
membrane (Amersham, UK) by overnight alkali capillary
blotting with the use of 0.4 M sodium hydroxide.
For hybridisation, filters were placed in roller bottles
(Hybaid, UK) with a solution (60 ,ul cm-2) containing 50%
(v/v) formamide, 0.1% sodium dodecyl sulphate (SDS),
5 x Denhardt's solution (0.1% each of polyvinylpyrrolidine,
bovine serum albumin and Ficoll), 5 mM EDTA, 75 mM
sodium chloride, 250 ,ug ml-' denatured sonicated salmon
sperm DNA, and incubated at 42°C for 4-6 h. After this
time, the relevant probe (either plasmid or PCR product),
labelled with [32P]dCTP (to specific activities between 5 x 109
and 5 x I09 cpm jig-l DNA) using the random primer
method, was added and hybridisation was continued for a
further 16-20 h. Filters were subsequently washed in
2 x standard saline citrate and 0.5% SDS for 15 min at
42°C with four changes of buffer, and then in 0.1 x standard
saline citrate and 0.5% SDS for 15 min at 650C with two
changes of buffer, and exposed to Amersham Hyperfilm at
-70°C, using intensifying screens.
Identity of the K19 PCR product was verified by
sequencing several independent isolates using standard
methods (data not shown).
Results
RNA from all the histologically involved nodes yielded the
expected 460 bp K19 PCR product. Of the 530 histologically
negative nodes, 106 (20%) gave a K19 product detectable by
Southern hybridisation, indicating the presence of tumour
cells in 23/75 (30.6%) of the histologically staged node-
negative patients. Table II shows the number of nodes
examined per patient and the number which were positive.
Seventeen out of twenty-three patients had more than one
positive node: 5/23 patients had four or more nodes positive
by PCR. All the normal nodes had amplified GAPDH but
displayed no K19 product. When all 125 patients were
considered, the presence of the K19 product in lymph nodes
was associated with the presence of lymphovascular invasion
in the primary (P<0.01), as well as with tumour size
(P<0.001) and grade (P=0.01), but not with receptor or
menopausal status. In the histologically node-negative
patients, there was a weak correlation with tumour grade
(P=0.05) and tumour size (P<0.05).
Sections from 33 randomly selected nodes that were
negative by histological examination but positive for K19
mRNA expression by RT-PCR were examined for presence
of K19 protein by immunohistochemistry; only three cases
(9%) were found to have positive staining in morphologically
identifiable tumour cells. In one lymph node, only one of two
sections examined had three positively stained tumour cells
visible; the other two lymph nodes had small clusters of
positive tumour cells. Forty-one randomly selected nodes that
were negative for both K19 mRNA expression and histology
were also negative for immunocytochemistry.
Discussion
Our results show that we can detect mRNA for the epithelial
marker K19 in the axillary lymph nodes of almost one-third
of patients who have no evidence of tumour involvement on
conventional histological examination. This is the expected
proportion of patients at risk of early relapse (Fisher et al.,
1981).
The increased detection may be due to our ability to study
a more representative proportion of the tissue compared with
1-4 sections. This increases the chance of detecting tumour
cells if these are relatively few (Trojani et al., 1987; Neville et
al., 1990; Mansi et al., 1991).
The patients in this study had a preponderance of small
carcinomas (Table I), and thus the test may be particularly
relevant for patients with early stage cancers that are now
being diagnosed using screening (de Koning et al., 1995).
The PCR method has the potential for automation and is
applicable to other epithelial cancers that express K19
(Bartek et al., 1985). There was a significant correlation
between the presence of PCR-detected micrometastases and
tumour size in conventionally node-negative staged patients,
but prognostic significance will be determined after longer
follow-up time.
Recently, Krismann et al. (1995) reported that a low level
of CK-19 mRNA could be found in peripheral blood in
normal control subjects. However, these authors used
different sets of primaries and did not appear to control for
the possibility that, unless specific precautions are taken,
small numbers of normal dermal epithelial cells can be
aspirated on collecting the blood sample.
Others have used PCR to detect the polymorphic epithelial
mucin gene product, but only 15 patients were studied
(Nogushi et al., 1994). Our results have shown that this gene
can be expressed in normal lymph nodes (Schoenfeld et al.,
1994).
We conclude that measurement of K19 mRNA in axillary
lymph nodes by PCR amplification is a more useful means of
detecting micrometastases and may have a role in identifying
a group of patients who would benefit from earlier adjuvant
chemotherapy and who would otherwise be denied this.
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